Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
|Videos|May 12, 2021
Dr. Chad Ellimoottil on the “virtual first” care model
Author(s)Urology Times staff
Ellimoottil also discusses the status of his own practice with regards to in-person vs telemedicine visits.
Advertisement
“[The] virtual first model has been adopted by a lot of providers and then also patients seem to be liking [it] a lot too,” says Chad Ellimoottil, MD, MS, in this video. Ellimoottil is Assistant Professor of Urology and Director of the University of Michigan’s Telehealth Research Incubator.
Advertisement
Related to this article
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
2
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
3
FDA updates in urology: October 2026
4
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
5